Category — Healthcare
Mylan Pharmaceuticals Private Limited, the Indian subsidiary of Mylan Inc., has entered into an agreement with Gilead Sciences, under which it has been appointed the exclusive distributor of Sovaldi® (sofosbuvir 400mg tablets) and Harvoni®(ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India. Mylan expects to begin distribution of Sovaldi in India in Q2 2015. Sovaldi received regulatory approval in India in January 2015 – the first country in Asia to approve the medicine.
Mylan President Rajiv Malik said that Hepatitis C was a growing public health concern, and Mylan was proud to partner with Gilead for life-saving medications for the 12 million hepatitis C patients in India.
February 25, 2015 No Comments
According to a PricewaterhouseCoopers report quoted in Outlook Magazine, the Indian healthcare delivery system has limited resources and will need an investment of $245 billion to deliver desired outcomes in the next two decades. India needs 3.5 million new hospital beds, 3 million doctors and 6 million nurses over a period of 20 years, it added.
Other than the mentioned physical infrastructure, poor health outcomes such as low life expectancy, high infant and maternal mortality rates will also need to be addressed:
- India must increase life expectancy at birth from 66 years in 2012 to 71 years by 2024 and to 80 years by 2034.
- Infant mortality rate (number of infant deaths per 1000 live births), needs to decrease from 44 to 31 in 2024 and to 12 in 2034.
- Maternal mortality rate (number of maternal deaths per 100,000 live births), which is at 190 today, could decrease to 124 in 2024 to 27 in 2034.
To achieve these targets, healthcare providers must focus on improving the reach, quality, and affordability of healthcare exhorts the report. It further suggests that India can leverage its strength as a world leader in vaccine manufacturing ─ it contributes 60% of global production − to sharpen its focus on preventive care.
January 28, 2015 No Comments
India suffers from the double burden of rising obesity and diabetes. The country has at least 65 million diabetes patients, and about 80 percent of those cases are correlated with obesity.
The rise of India’s middle class in the past two decades has ushered a penchant for unhealthy processed food and snacks as well as for fast food. The obesity rate among teenagers has been attributed to an addiction to junk food and gadgets which preclude physical activity. The number of gyms and yoga studios have increased, but there are few commercial diet programs such as NutriSystem or Weight Watchers and bariatric surgery with a price tag of approximately $5000 has become a quick fix for those who can afford it, reports the Washington Post. Pradeep Chowbey, chief bariatric surgeon at Max Healthcare hospital in New Delhi and former president of the Obesity and Metabolic Surgery Society of India says that about 18,000 weight-loss surgeries were conducted in India in 2014, up from 800 just five years ago.
Experts predict that the booming $2 billion medical tourism industry in India will grow to include bariatric surgeries.
January 26, 2015 No Comments
An “Apex Committee for Clinical Trials” has been constituted by the Union Health Ministry on the directive of the Supreme Court of India. Outsourcing Pharma.Com reports that this committee now requires developers of cancer treatments approved without trials to monitor the first 500 patients to assess the drug’s safety and efficacy. An analysis of the data acquired will need to be submitted to the Drugs Controller General of India, who will then forward it to the Technical and Apex Committees for scrutiny.
The new recommendation comes after the marketing approval was granted to Merck’s Zolinza (vorinostat), and Medivation and Astellas’ Xtandi (enzaltuamide), both treatments for cancer. Further, the Apex and the Technical Committees have approved 28 of 31 submissions for clinical trials.
January 11, 2015 No Comments
The Health Ministry of India proposes to constitute a Medical Devices Technical Advisory Board to counsel the federal and state government on technical issues related to medical devices.
The Director General, Indian Council of Medical Research, will be the ex officio chairperson of the board, and the Drugs Controller General of India will be the ex officio member secretary.
Besides these officials, the board will have one expert each from the departments of:
- Science and Technology
- Atomic Energy
- Electronics and Information Technology
- Federal Testing Laboratories
- The Bureau of Indian Standards
- The Defense Research and Development Organization
- The Indian Commission for Drugs
Other members will be inducted from the following areas:
- Biomedical technology
- Biomaterial or polymer technology
- Consumer affairs
- Clinical trials
- Medical devices and in vitro diagnostics industries
The nominated members will have a three year term in office.
January 9, 2015 No Comments